Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic Review

Ensysce Biosciences (NASDAQ:ENSC) shares are up on Friday as the company has initiated a review of strategic alternatives aimed at enhancing shareholder value.The company on Wednesday announced that its Board of Directors is exploring a range of strategic alternatives, which may include partnerships, licensing arrangements, or asset sales.The strategic review is intended to support the advancement of its proprietary technologies, specifically the TAAP and MPAR platforms.“Our technologies were designed to fu ...